Sionna cuts 46% of staff, pivots to new CF drug combination

September 14, 2026 4:01 PM

Sionna Therapeutics (Nasdaq: SION) announced plans to advance its SION-451 + SION-2222 dual combination into a Phase 2a proof-of-concept trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found